Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Cybin Inc N.CYBN

Alternate Symbol(s):  CYBN

Healthcare Drug Manufacturers - Specialty & Generic Psychedelics
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary... see more

NEO:CYBN - Post Discussion

Cybin Inc > Breakthrough Tech to Measure Real-Time Brain Activity
View:
Post by TrojanHorse82 on Mar 29, 2021 12:36am

Breakthrough Tech to Measure Real-Time Brain Activity

Cybin (NEO: CYBN) (OTC: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently announced its collaboration with neurotech pioneer HI LLC dba Kernel. According to the update, CYBN will leverage Kernel Flow, Kernel’s breakthrough technology, for its upcoming clinical work to quantify brain activity in real time during psychedelic experiences.
Be the first to comment on this post
Cybin Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities